KRAS and hematopoietic and lymphoid system neoplasm: Since some AML cell lines harbor SOS1 mutations and are dependent on SOS1 for survival, a combination of SOS1 and MEK inhibitors may be an attractive strategy for the treatment of blood cancers containing KRAS mutations [16].